disease,drug,phase,status,target,num_ev_strings
non-small cell lung carcinoma,ERLOTINIB,2,Completed,EGFR,75
non-small cell lung carcinoma,OSIMERTINIB,2,Recruiting,EGFR,38
non-small cell lung carcinoma,ERLOTINIB,1,Completed,EGFR,31
non-small cell lung carcinoma,ERLOTINIB,3,Completed,EGFR,28
non-small cell lung carcinoma,OSIMERTINIB,1,Recruiting,EGFR,28
non-small cell lung carcinoma,ERLOTINIB,2,Unknown status,EGFR,24
lung carcinoma,ERLOTINIB,2,Completed,EGFR,23
colorectal carcinoma,CETUXIMAB,2,Completed,EGFR,23
non-small cell lung carcinoma,GEFITINIB,2,Completed,EGFR,22
non-small cell lung carcinoma,CETUXIMAB,2,Completed,EGFR,21
head and neck malignant neoplasia,CETUXIMAB,2,Completed,EGFR,20
breast carcinoma,LAPATINIB,2,Completed,EGFR,20
neoplasm,ERLOTINIB,1,Completed,EGFR,20
non-small cell lung carcinoma,OSIMERTINIB,1,"Active, not recruiting",EGFR,18
non-small cell lung carcinoma,ERLOTINIB,2,Terminated,EGFR,18
metastatic colorectal cancer,CETUXIMAB,2,Completed,EGFR,16
non-small cell lung carcinoma,ERLOTINIB,1,Terminated,EGFR,16
neoplasm,AFATINIB,1,Completed,EGFR,16
non-small cell lung carcinoma,GEFITINIB,2,Unknown status,EGFR,15
breast carcinoma,LAPATINIB,1,Completed,EGFR,15
breast neoplasm,LAPATINIB,2,Completed,EGFR,15
pancreatic carcinoma,ERLOTINIB,2,Completed,EGFR,15
breast carcinoma,GEFITINIB,2,Completed,EGFR,14
breast carcinoma,NERATINIB,1,Completed,EGFR,14
breast carcinoma,NERATINIB,2,Recruiting,EGFR,14
breast carcinoma,LAPATINIB,2,Terminated,EGFR,13
non-small cell lung carcinoma,GEFITINIB,3,Completed,EGFR,13
pancreatic carcinoma,ERLOTINIB,1,Completed,EGFR,12
colorectal carcinoma,PANITUMUMAB,2,Completed,EGFR,12
breast neoplasm,LAPATINIB,1,Completed,EGFR,11
lung carcinoma,GEFITINIB,2,Completed,EGFR,11
colorectal carcinoma,CETUXIMAB,1,Completed,EGFR,10
pancreatic carcinoma,CETUXIMAB,2,Completed,EGFR,10
lung carcinoma,ERLOTINIB,1,Completed,EGFR,10
non-small cell lung carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,10
colorectal carcinoma,CETUXIMAB,2,Terminated,EGFR,10
pancreatic carcinoma,ERLOTINIB,2,Terminated,EGFR,9
non-small cell lung carcinoma,AFATINIB,2,Completed,EGFR,9
cancer,ERLOTINIB,1,Completed,EGFR,9
head and neck malignant neoplasia,GEFITINIB,2,Completed,EGFR,8
neoplasm,CETUXIMAB,1,Completed,EGFR,8
non-small cell lung carcinoma,DACOMITINIB,2,Completed,EGFR,8
non-small cell lung carcinoma,OSIMERTINIB,2,Not yet recruiting,EGFR,8
metastatic colorectal cancer,PANITUMUMAB,2,Recruiting,EGFR,8
head and neck malignant neoplasia,CETUXIMAB,1,Completed,EGFR,8
non-small cell lung carcinoma,OSIMERTINIB,2,"Active, not recruiting",EGFR,8
non-small cell lung carcinoma,OSIMERTINIB,3,"Active, not recruiting",EGFR,8
breast carcinoma,LAPATINIB,2,"Active, not recruiting",EGFR,8
lung carcinoma,CETUXIMAB,2,Completed,EGFR,8
breast carcinoma,LAPATINIB,1,Terminated,EGFR,8
neoplasm,NERATINIB,1,Completed,EGFR,8
metastatic colorectal cancer,CETUXIMAB,3,Completed,EGFR,7
metastatic colorectal cancer,CETUXIMAB,1,Completed,EGFR,7
non-small cell lung carcinoma,VANDETANIB,2,Completed,EGFR,7
metastatic colorectal cancer,CETUXIMAB,2,Recruiting,EGFR,7
non-small cell lung carcinoma,ERLOTINIB,4,Completed,EGFR,7
metastatic colorectal cancer,PANITUMUMAB,2,Completed,EGFR,7
neoplasm,GEFITINIB,1,Completed,EGFR,7
non-small cell lung carcinoma,GEFITINIB,1,Completed,EGFR,7
colorectal carcinoma,CETUXIMAB,3,Completed,EGFR,7
non-small cell lung carcinoma,ERLOTINIB,3,Terminated,EGFR,7
non-small cell lung carcinoma,AFATINIB,3,Completed,EGFR,6
gliosarcoma,ERLOTINIB,2,Completed,EGFR,6
colorectal carcinoma,PANITUMUMAB,1,Completed,EGFR,6
breast neoplasm,LAPATINIB,3,"Active, not recruiting",EGFR,6
non-small cell lung carcinoma,AFATINIB,2,"Active, not recruiting",EGFR,6
head and neck malignant neoplasia,CETUXIMAB,3,"Active, not recruiting",EGFR,6
breast carcinoma,LAPATINIB,3,"Active, not recruiting",EGFR,6
non-small cell lung carcinoma,CETUXIMAB,1,Completed,EGFR,6
head and neck squamous cell carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,6
breast carcinoma,ERLOTINIB,2,Completed,EGFR,6
neoplasm,DACOMITINIB,1,Completed,EGFR,6
breast carcinoma,NERATINIB,2,Completed,EGFR,6
breast neoplasm,AFATINIB,2,Completed,EGFR,6
non-small cell lung carcinoma,GEFITINIB,1,"Active, not recruiting",EGFR,6
colorectal carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,6
pancreatic adenocarcinoma,ERLOTINIB,2,Completed,EGFR,6
head and neck malignant neoplasia,ERLOTINIB,2,Completed,EGFR,6
metastatic colorectal cancer,CETUXIMAB,2,Terminated,EGFR,6
gastric carcinoma,CETUXIMAB,2,Completed,EGFR,6
non-small cell lung carcinoma,GEFITINIB,3,Recruiting,EGFR,6
prostate carcinoma,GEFITINIB,2,Completed,EGFR,6
cancer,CETUXIMAB,1,Completed,EGFR,6
non-small cell lung carcinoma,ERLOTINIB,3,"Active, not recruiting",EGFR,6
lung carcinoma,GEFITINIB,1,Completed,EGFR,6
breast carcinoma,LAPATINIB,1,"Active, not recruiting",EGFR,5
esophageal carcinoma,CETUXIMAB,2,Completed,EGFR,5
head and neck squamous cell carcinoma,CETUXIMAB,2,Completed,EGFR,5
breast carcinoma,LAPATINIB,2,Unknown status,EGFR,5
breast carcinoma,ERLOTINIB,1,Completed,EGFR,5
non-small cell lung carcinoma,GEFITINIB,1,Recruiting,EGFR,5
colorectal neoplasm,CETUXIMAB,2,Completed,EGFR,5
breast neoplasm,LAPATINIB,2,Terminated,EGFR,5
non-small cell lung carcinoma,GEFITINIB,3,"Active, not recruiting",EGFR,5
head and neck malignant neoplasia,ERLOTINIB,1,Completed,EGFR,5
squamous cell carcinoma,CETUXIMAB,2,Completed,EGFR,5
head and neck squamous cell carcinoma,CETUXIMAB,3,"Active, not recruiting",EGFR,5
non-small cell lung carcinoma,ERLOTINIB,1,"Active, not recruiting",EGFR,5
hepatocellular carcinoma,ERLOTINIB,2,Completed,EGFR,5
breast carcinoma,ERLOTINIB,2,Terminated,EGFR,5
squamous cell carcinoma,CETUXIMAB,1,Recruiting,EGFR,5
rectum cancer,CETUXIMAB,2,Unknown status,EGFR,4
cancer,VARLITINIB,1,Completed,EGFR,4
prostate carcinoma,ERLOTINIB,2,Completed,EGFR,4
non-small cell lung carcinoma,CETUXIMAB,3,Completed,EGFR,4
colorectal adenocarcinoma,CETUXIMAB,1,Completed,EGFR,4
rectum cancer,CETUXIMAB,2,Completed,EGFR,4
peritoneal neoplasm,GEFITINIB,2,Completed,EGFR,4
esophageal carcinoma,CETUXIMAB,2,Terminated,EGFR,4
lung carcinoma,OSIMERTINIB,1,Recruiting,EGFR,4
colorectal carcinoma,CETUXIMAB,2,Unknown status,EGFR,4
lung carcinoma,OSIMERTINIB,2,"Active, not recruiting",EGFR,4
pancreatic carcinoma,ERLOTINIB,3,Completed,EGFR,4
ovarian carcinoma,GEFITINIB,2,Completed,EGFR,4
head and neck squamous cell carcinoma,CETUXIMAB,2,Recruiting,EGFR,4
colorectal carcinoma,GEFITINIB,2,Completed,EGFR,4
lung carcinoma,OSIMERTINIB,2,Recruiting,EGFR,4
breast neoplasm,LAPATINIB,3,Completed,EGFR,4
cancer,CETUXIMAB,2,Completed,EGFR,4
breast neoplasm,NERATINIB,1,Completed,EGFR,4
cancer,BMS-690514,1,Completed,EGFR,4
breast neoplasm,NERATINIB,2,Recruiting,EGFR,4
lung carcinoma,ERLOTINIB,2,Terminated,EGFR,4
non-small cell lung carcinoma,DACOMITINIB,1,Completed,EGFR,4
neoplasm,PANITUMUMAB,1,Completed,EGFR,4
non-small cell lung carcinoma,NECITUMUMAB,1,"Active, not recruiting",EGFR,4
neoplasm,LAPATINIB,1,Completed,EGFR,4
metastatic colorectal cancer,CETUXIMAB,2,"Active, not recruiting",EGFR,4
breast carcinoma,LAPATINIB,2,Recruiting,EGFR,4
neoplasm,ERLOTINIB,2,Completed,EGFR,4
non-small cell lung carcinoma,GEFITINIB,2,Recruiting,EGFR,4
gliosarcoma,ERLOTINIB,1,Completed,EGFR,4
non-small cell lung carcinoma,ERLOTINIB,3,Unknown status,EGFR,4
breast carcinoma,CETUXIMAB,2,Completed,EGFR,4
breast carcinoma,NERATINIB,1,Recruiting,EGFR,4
non-small cell lung carcinoma,NERATINIB,2,Completed,EGFR,4
glioblastoma multiforme,DACOMITINIB,2,Completed,EGFR,4
breast carcinoma,NERATINIB,3,"Active, not recruiting",EGFR,4
squamous cell carcinoma,DACOMITINIB,2,Unknown status,EGFR,4
head and neck squamous cell carcinoma,CETUXIMAB,1,"Active, not recruiting",EGFR,4
head and neck malignant neoplasia,CETUXIMAB,2,"Active, not recruiting",EGFR,4
head and neck malignant neoplasia,CETUXIMAB,2,Unknown status,EGFR,4
metastatic colorectal cancer,PANITUMUMAB,3,Completed,EGFR,4
non-small cell lung carcinoma,ERLOTINIB,1,Recruiting,EGFR,4
non-small cell lung carcinoma,ERLOTINIB,3,Recruiting,EGFR,4
colorectal carcinoma,CETUXIMAB,3,Unknown status,EGFR,3
lung carcinoma,GEFITINIB,3,Unknown status,EGFR,3
non-small cell lung carcinoma,AFATINIB,1,Completed,EGFR,3
renal carcinoma,ERLOTINIB,2,Completed,EGFR,3
squamous cell carcinoma,NIMOTUZUMAB,2,Withdrawn,EGFR,3
non-small cell lung carcinoma,ERLOTINIB,2,Recruiting,EGFR,3
cancer,ERLOTINIB,2,Recruiting,EGFR,3
non-small cell lung carcinoma,VANDETANIB,3,Completed,EGFR,3
cancer,ERLOTINIB,2,Completed,EGFR,3
esophageal carcinoma,CETUXIMAB,2,Unknown status,EGFR,3
cholangiocarcinoma,PANITUMUMAB,2,Completed,EGFR,3
squamous cell carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,3
metastatic colorectal cancer,PANITUMUMAB,1,Completed,EGFR,3
head and neck malignant neoplasia,CETUXIMAB,1,Terminated,EGFR,3
prostate carcinoma,LAPATINIB,2,Completed,EGFR,3
head and neck squamous cell carcinoma,CETUXIMAB,1,Terminated,EGFR,3
central nervous system cancer,VANDETANIB,1,Completed,EGFR,3
prostate carcinoma,VANDETANIB,2,Completed,EGFR,3
neoplasm,ERLOTINIB,1,Terminated,EGFR,3
non-small cell lung carcinoma,GEFITINIB,4,Completed,EGFR,3
cervical carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,3
lung carcinoma,GEFITINIB,3,Completed,EGFR,3
cancer,LAPATINIB,2,Terminated,EGFR,3
cancer,LAPATINIB,2,Completed,EGFR,3
colorectal carcinoma,GEFITINIB,1,Completed,EGFR,3
cancer,LAPATINIB,1,Completed,EGFR,3
nasopharyngeal neoplasm,CETUXIMAB,2,Completed,EGFR,3
colorectal carcinoma,ERLOTINIB,1,Completed,EGFR,3
head and neck squamous cell carcinoma,PANITUMUMAB,2,Completed,EGFR,3
thyroid carcinoma,VANDETANIB,3,"Active, not recruiting",EGFR,3
head and neck squamous cell carcinoma,CETUXIMAB,3,Completed,EGFR,3
breast neoplasm,LAPATINIB,2,"Active, not recruiting",EGFR,3
central nervous system cancer,ERLOTINIB,1,Completed,EGFR,3
anaplastic astrocytoma,ERLOTINIB,1,Completed,EGFR,3
squamous cell carcinoma,CETUXIMAB,1,Unknown status,EGFR,3
head and neck squamous cell carcinoma,CETUXIMAB,1,Completed,EGFR,3
squamous cell carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,3
lung carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,3
breast carcinoma,VANDETANIB,2,Terminated,EGFR,3
metastatic colorectal cancer,PANITUMUMAB,2,Unknown status,EGFR,3
breast carcinoma,LAPATINIB,3,Unknown status,EGFR,3
neoplasm,CETUXIMAB,2,Completed,EGFR,3
nasopharyngeal neoplasm,NIMOTUZUMAB,2,Recruiting,EGFR,3
breast carcinoma,LAPATINIB,3,Recruiting,EGFR,3
breast carcinoma,LAPATINIB,3,Completed,EGFR,3
colorectal carcinoma,PANITUMUMAB,2,"Active, not recruiting",EGFR,3
breast carcinoma,LAPATINIB,2,Withdrawn,EGFR,3
metastatic colorectal cancer,CETUXIMAB,1,Recruiting,EGFR,3
head and neck malignant neoplasia,GEFITINIB,1,Completed,EGFR,3
cancer,CETUXIMAB,1,"Active, not recruiting",EGFR,3
metastatic colorectal cancer,CETUXIMAB,3,Recruiting,EGFR,3
renal cell carcinoma,ERLOTINIB,2,Completed,EGFR,3
head and neck malignant neoplasia,CETUXIMAB,3,Completed,EGFR,3
breast neoplasm,LAPATINIB,2,Withdrawn,EGFR,3
esophageal carcinoma,GEFITINIB,2,Completed,EGFR,3
non-small cell lung carcinoma,BRIGATINIB,2,Recruiting,EGFR,3
colorectal carcinoma,PANITUMUMAB,2,Recruiting,EGFR,3
breast carcinoma,GEFITINIB,2,Terminated,EGFR,3
colorectal carcinoma,CETUXIMAB,2,Not yet recruiting,EGFR,3
pancreatic carcinoma,CETUXIMAB,2,Terminated,EGFR,3
non-small cell lung carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,3
colorectal carcinoma,PANITUMUMAB,1,Terminated,EGFR,2
ovarian carcinoma,ERLOTINIB,2,Completed,EGFR,2
hepatocellular carcinoma,ERLOTINIB,2,Terminated,EGFR,2
colorectal carcinoma,PANITUMUMAB,2,Unknown status,EGFR,2
gliosarcoma,VANDETANIB,1,Completed,EGFR,2
head and neck squamous cell carcinoma,CETUXIMAB,1,Recruiting,EGFR,2
colorectal carcinoma,NERATINIB,1,Withdrawn,EGFR,2
non-small cell lung carcinoma,GEFITINIB,2,Not yet recruiting,EGFR,2
colorectal cancer,OSIMERTINIB,2,Completed,EGFR,2
head and neck malignant neoplasia,ERLOTINIB,2,"Active, not recruiting",EGFR,2
non-small cell lung carcinoma,ERLOTINIB,3,Withdrawn,EGFR,2
colorectal carcinoma,CETUXIMAB,1,Not yet recruiting,EGFR,2
colorectal carcinoma,CETUXIMAB,1,Terminated,EGFR,2
laryngeal neoplasm,CETUXIMAB,2,Terminated,EGFR,2
colorectal carcinoma,CETUXIMAB,1,Withdrawn,EGFR,2
head and neck malignant neoplasia,CUDC-101,1,Completed,EGFR,2
colorectal carcinoma,CETUXIMAB,2,Recruiting,EGFR,2
non-small cell lung carcinoma,GEFITINIB,1,Unknown status,EGFR,2
head and neck malignant neoplasia,CETUXIMAB,3,Terminated,EGFR,2
head and neck malignant neoplasia,CETUXIMAB,2,Withdrawn,EGFR,2
colorectal carcinoma,CETUXIMAB,2,Withdrawn,EGFR,2
head and neck malignant neoplasia,CETUXIMAB,2,Terminated,EGFR,2
colorectal carcinoma,CETUXIMAB,3,Terminated,EGFR,2
colorectal carcinoma,PANITUMUMAB,3,Completed,EGFR,2
head and neck malignant neoplasia,CETUXIMAB,2,Recruiting,EGFR,2
colorectal carcinoma,DACOMITINIB,1,Recruiting,EGFR,2
hypopharyngeal carcinoma,CETUXIMAB,2,Completed,EGFR,2
colorectal carcinoma,ERLOTINIB,3,Completed,EGFR,2
non-small cell lung carcinoma,GEFITINIB,2,"Active, not recruiting",EGFR,2
colorectal carcinoma,PANITUMUMAB,3,"Active, not recruiting",EGFR,2
non-small cell lung carcinoma,DACOMITINIB,1,Suspended,EGFR,2
non-small cell lung carcinoma,GEFITINIB,2,Terminated,EGFR,2
esophageal carcinoma,PANITUMUMAB,1,Completed,EGFR,2
non-small cell lung carcinoma,PYROTINIB,2,Unknown status,EGFR,2
non-small cell lung carcinoma,NECITUMUMAB,1,Recruiting,EGFR,2
esophageal carcinoma,ERLOTINIB,2,Completed,EGFR,2
non-small cell lung carcinoma,NECITUMUMAB,2,Completed,EGFR,2
esophageal carcinoma,ERLOTINIB,2,Terminated,EGFR,2
non-small cell lung carcinoma,POZIOTINIB,2,Recruiting,EGFR,2
esophageal carcinoma,GEFITINIB,1,Terminated,EGFR,2
esophageal carcinoma,GEFITINIB,2,Terminated,EGFR,2
non-small cell lung carcinoma,ERLOTINIB,1,Withdrawn,EGFR,2
non-small cell lung carcinoma,EGF816,1,Recruiting,EGFR,2
esophageal carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,2
non-small cell lung carcinoma,ERLOTINIB,1,Unknown status,EGFR,2
ovarian carcinoma,CETUXIMAB,2,Completed,EGFR,2
non-small cell lung carcinoma,OSIMERTINIB,4,n/a,EGFR,2
non-small cell lung carcinoma,OSIMERTINIB,4,Not yet recruiting,EGFR,2
pancreatic adenocarcinoma,ERLOTINIB,1,"Active, not recruiting",EGFR,2
non-small cell lung carcinoma,OSIMERTINIB,3,Recruiting,EGFR,2
non-small cell lung carcinoma,OSIMERTINIB,2,Completed,EGFR,2
non-small cell lung carcinoma,OSIMERTINIB,1,Not yet recruiting,EGFR,2
non-small cell lung carcinoma,OSIMERTINIB,1,Completed,EGFR,2
gastric adenocarcinoma,CETUXIMAB,2,Completed,EGFR,2
non-small cell lung carcinoma,OLMUTINIB,2,"Active, not recruiting",EGFR,2
non-small cell lung carcinoma,NIMOTUZUMAB,2,Terminated,EGFR,2
gastric carcinoma,LAPATINIB,2,Completed,EGFR,2
head and neck squamous cell carcinoma,DACOMITINIB,1,Completed,EGFR,2
head and neck malignant neoplasia,ZALUTUMUMAB,3,Completed,EGFR,2
head and neck squamous cell carcinoma,DACOMITINIB,2,Completed,EGFR,2
head and neck squamous cell carcinoma,ERLOTINIB,1,Completed,EGFR,2
colorectal carcinoma,VANDETANIB,1,Completed,EGFR,2
colorectal neoplasm,AFATINIB,2,Completed,EGFR,2
non-small cell lung carcinoma,CETUXIMAB,2,Terminated,EGFR,2
oral cavity cancer,DACOMITINIB,1,Completed,EGFR,2
hepatocellular carcinoma,CETUXIMAB,2,Completed,EGFR,2
glioblastoma multiforme,OSIMERTINIB,2,Recruiting,EGFR,2
non-small cell lung carcinoma,GEFITINIB,3,Not yet recruiting,EGFR,2
glioblastoma multiforme,NERATINIB,2,Recruiting,EGFR,2
non-small cell lung carcinoma,GEFITINIB,3,Terminated,EGFR,2
non-small cell lung carcinoma,GEFITINIB,3,Unknown status,EGFR,2
glioblastoma multiforme,GEFITINIB,2,Completed,EGFR,2
non-small cell lung carcinoma,GEFITINIB,3,Withdrawn,EGFR,2
non-small cell lung carcinoma,DACOMITINIB,1,Recruiting,EGFR,2
non-small cell lung carcinoma,VANDETANIB,1,Terminated,EGFR,2
non-small cell lung carcinoma,VANDETANIB,1,Completed,EGFR,2
non-small cell lung carcinoma,DACOMITINIB,1,Terminated,EGFR,2
non-small cell lung carcinoma,DACOMITINIB,2,"Active, not recruiting",EGFR,2
non-small cell lung carcinoma,GEFITINIB,4,Terminated,EGFR,2
ependymoma,ERLOTINIB,2,Terminated,EGFR,2
non-small cell lung carcinoma,DACOMITINIB,3,"Active, not recruiting",EGFR,2
non-small cell lung carcinoma,ERLOTINIB,2,Withdrawn,EGFR,2
non-small cell lung carcinoma,DACOMITINIB,3,Completed,EGFR,2
esophageal carcinoma,CETUXIMAB,1,Completed,EGFR,2
colorectal cancer,CETUXIMAB,2,Completed,EGFR,2
lung carcinoma,DACOMITINIB,3,Completed,EGFR,2
colorectal adenocarcinoma,VANDETANIB,1,Completed,EGFR,2
breast carcinoma,NERATINIB,2,Not yet recruiting,EGFR,2
neoplasm,OSIMERTINIB,1,Completed,EGFR,2
male breast carcinoma,LAPATINIB,2,Completed,EGFR,2
neoplasm,OSIMERTINIB,1,"Active, not recruiting",EGFR,2
neoplasm,NERATINIB,1,Terminated,EGFR,2
breast carcinoma,PYROTINIB,3,Recruiting,EGFR,2
mesothelioma,ERLOTINIB,2,Completed,EGFR,2
mesothelioma,GEFITINIB,2,Completed,EGFR,2
squamous cell carcinoma,AFATINIB,2,Completed,EGFR,2
breast carcinoma,PYROTINIB,1,Recruiting,EGFR,2
breast carcinoma,PYROTINIB,1,Completed,EGFR,2
neoplasm,NECITUMUMAB,2,Completed,EGFR,2
metastasis,DACOMITINIB,1,Completed,EGFR,2
squamous cell carcinoma,CETUXIMAB,1,"Active, not recruiting",EGFR,2
squamous cell carcinoma,CETUXIMAB,1,Completed,EGFR,2
neoplasm,NECITUMUMAB,1,Completed,EGFR,2
neoplasm,OSIMERTINIB,4,n/a,EGFR,2
lung carcinoma,VANDETANIB,2,Terminated,EGFR,2
breast neoplasm,LAPATINIB,1,"Active, not recruiting",EGFR,2
lung carcinoma,OSIMERTINIB,3,Completed,EGFR,2
lung carcinoma,GEFITINIB,2,Unknown status,EGFR,2
cancer,ERLOTINIB,2,Terminated,EGFR,2
lung carcinoma,OSIMERTINIB,2,Not yet recruiting,EGFR,2
cancer,ERLOTINIB,1,"Active, not recruiting",EGFR,2
renal carcinoma,GEFITINIB,2,Completed,EGFR,2
lung carcinoma,OSIMERTINIB,3,"Active, not recruiting",EGFR,2
renal cell carcinoma,ERLOTINIB,1,Terminated,EGFR,2
lung carcinoma,VANDETANIB,2,Completed,EGFR,2
cancer,AC-480,1,Completed,EGFR,2
bronchoalveolar adenocarcinoma,ERLOTINIB,2,Completed,EGFR,2
renal cell carcinoma,LAPATINIB,1,Completed,EGFR,2
breast neoplasm,NERATINIB,2,Completed,EGFR,2
breast neoplasm,NERATINIB,1,Recruiting,EGFR,2
breast neoplasm,LAPATINIB,2,Recruiting,EGFR,2
breast carcinoma,NERATINIB,4,n/a,EGFR,2
breast carcinoma,LAPATINIB,1,Unknown status,EGFR,2
rectum cancer,CETUXIMAB,2,Terminated,EGFR,2
squamous cell carcinoma,CETUXIMAB,3,"Active, not recruiting",EGFR,2
upper aerodigestive tract neoplasm,AFATINIB,3,Terminated,EGFR,2
adenocarcinoma,CETUXIMAB,2,Completed,EGFR,2
upper aerodigestive tract neoplasm,CETUXIMAB,1,Completed,EGFR,2
upper aerodigestive tract neoplasm,CETUXIMAB,2,Completed,EGFR,2
neoplasm,DULIGOTUZUMAB,1,Completed,EGFR,2
upper aerodigestive tract neoplasm,CETUXIMAB,2,Unknown status,EGFR,2
Fibrolamellar Carcinoma,NERATINIB,2,Recruiting,EGFR,2
upper aerodigestive tract neoplasm,DACOMITINIB,2,Completed,EGFR,2
neoplasm,DACOMITINIB,1,Recruiting,EGFR,2
Fallopian Tube Carcinoma,GEFITINIB,2,Completed,EGFR,2
Fallopian Tube Carcinoma,ERLOTINIB,2,Completed,EGFR,2
nasopharyngeal neoplasm,NIMOTUZUMAB,3,Unknown status,EGFR,2
neoplasm,CETUXIMAB,1,Unknown status,EGFR,2
neoplasm,AFATINIB,2,Recruiting,EGFR,2
neoplasm,CETUXIMAB,1,Terminated,EGFR,2
adenocarcinoma,OSIMERTINIB,2,Recruiting,EGFR,2
neoplasm,ERLOTINIB,3,Completed,EGFR,2
metastatic colorectal cancer,PANITUMUMAB,3,Recruiting,EGFR,2
squamous cell lung carcinoma,ERLOTINIB,2,Completed,EGFR,2
metastatic colorectal cancer,CETUXIMAB,2,Unknown status,EGFR,2
metastatic colorectal cancer,ERLOTINIB,2,Terminated,EGFR,2
brain neoplasm,DACOMITINIB,2,Terminated,EGFR,2
squamous cell carcinoma,OSIMERTINIB,2,Recruiting,EGFR,2
neoplasm,LAPATINIB,1,Terminated,EGFR,2
bladder carcinoma,PANITUMUMAB,2,Terminated,EGFR,2
neoplasm,GEFITINIB,2,Recruiting,EGFR,2
anaplastic oligodendroglioma,ERLOTINIB,1,Completed,EGFR,2
metastatic colorectal cancer,NERATINIB,2,Recruiting,EGFR,2
bladder carcinoma,GEFITINIB,2,Completed,EGFR,2
bladder carcinoma,ERLOTINIB,2,Completed,EGFR,2
biliary tract neoplasm,VARLITINIB,2,"Active, not recruiting",EGFR,2
thyroid carcinoma,VANDETANIB,1,Completed,EGFR,2
thyroid carcinoma,VANDETANIB,2,Completed,EGFR,2
rectum cancer,ERLOTINIB,1,Completed,EGFR,2
non-small cell lung carcinoma,AFATINIB,1,"Active, not recruiting",EGFR,2
lung carcinoma,ERLOTINIB,1,Withdrawn,EGFR,2
prostate adenocarcinoma,AFATINIB,2,Completed,EGFR,2
lung adenocarcinoma,ERLOTINIB,2,Completed,EGFR,2
carcinoma,NERATINIB,1,Completed,EGFR,2
lung adenocarcinoma,GEFITINIB,2,Not yet recruiting,EGFR,2
carcinoma,OSIMERTINIB,2,Recruiting,EGFR,2
lung carcinoma,ERLOTINIB,1,Unknown status,EGFR,2
colon carcinoma,CETUXIMAB,2,Recruiting,EGFR,2
lung adenocarcinoma,OSIMERTINIB,2,Recruiting,EGFR,2
peritoneal neoplasm,ERLOTINIB,2,Completed,EGFR,2
peritoneal neoplasm,CETUXIMAB,2,Completed,EGFR,2
central nervous system cancer,ERLOTINIB,2,Completed,EGFR,2
penile neoplasm,DACOMITINIB,2,Unknown status,EGFR,2
lung carcinoma,ERLOTINIB,1,"Active, not recruiting",EGFR,2
central nervous system cancer,GEFITINIB,2,Completed,EGFR,2
lung carcinoma,DACOMITINIB,0,Recruiting,EGFR,2
pancreatic carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,2
central nervous system cancer,NIMOTUZUMAB,2,Completed,EGFR,2
non-small cell lung carcinoma,AFATINIB,1,Unknown status,EGFR,2
cervical carcinoma,CETUXIMAB,2,Completed,EGFR,2
lung carcinoma,GEFITINIB,2,Recruiting,EGFR,2
non-small cell lung carcinoma,AFATINIB,2,Unknown status,EGFR,2
lung carcinoma,AFATINIB,2,"Active, not recruiting",EGFR,2
pancreatic carcinoma,PANITUMUMAB,2,Completed,EGFR,2
pancreatic carcinoma,PANITUMUMAB,1,Completed,EGFR,2
pharyngeal squamous cell carcinoma,CETUXIMAB,3,"Active, not recruiting",EGFR,2
pancreatic carcinoma,LAPATINIB,2,Terminated,EGFR,2
liver disease,DACOMITINIB,1,Not yet recruiting,EGFR,2
pancreatic carcinoma,CETUXIMAB,1,Completed,EGFR,2
lung carcinoma,ERLOTINIB,3,Completed,EGFR,2
non-small cell lung carcinoma,BMS-690514,2,Completed,EGFR,2
cancer,VANDETANIB,1,Completed,EGFR,2
lung carcinoma,ERLOTINIB,2,Unknown status,EGFR,2
prostate carcinoma,PANITUMUMAB,2,Completed,EGFR,2
lung adenocarcinoma,ERLOTINIB,1,Completed,EGFR,2
lung carcinoma,GEFITINIB,2,"Active, not recruiting",EGFR,2
cancer,OSIMERTINIB,3,"Active, not recruiting",EGFR,2
carcinoma,DACOMITINIB,1,Completed,EGFR,2
rectum cancer,CETUXIMAB,1,Completed,EGFR,2
carcinoma,DACOMITINIB,2,Completed,EGFR,2
lung carcinoma,ERLOTINIB,3,Unknown status,EGFR,2
non-small cell lung carcinoma,AFATINIB,3,"Active, not recruiting",EGFR,1
neoplasm,ERLOTINIB,4,n/a,EGFR,1
non-small cell lung carcinoma,BRIGATINIB,2,Not yet recruiting,EGFR,1
non-small cell lung carcinoma,BRIGATINIB,2,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,BRIGATINIB,0,Recruiting,EGFR,1
non-small cell lung carcinoma,AFATINIB,4,Completed,EGFR,1
neoplasm,ERLOTINIB,2,Unknown status,EGFR,1
non-small cell lung carcinoma,BRIGATINIB,3,Not yet recruiting,EGFR,1
non-small cell lung carcinoma,AFATINIB,2,Terminated,EGFR,1
neoplasm,FUTUXIMAB,1,Completed,EGFR,1
neoplasm,CETUXIMAB,1,Recruiting,EGFR,1
non-small cell lung carcinoma,AFATINIB,2,Suspended,EGFR,1
non-small cell lung carcinoma,AFATINIB,2,Recruiting,EGFR,1
non-small cell lung carcinoma,BRIGATINIB,4,n/a,EGFR,1
neoplasm,GEFITINIB,2,Completed,EGFR,1
non-small cell lung carcinoma,BRIGATINIB,3,"Active, not recruiting",EGFR,1
neoplasm,ERLOTINIB,1,Unknown status,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,3,Suspended,EGFR,1
neoplasm,ERLOTINIB,2,Recruiting,EGFR,1
neoplasm,ERLOTINIB,1,Withdrawn,EGFR,1
neoplasm,DEPATUXIZUMAB MAFODOTIN,1,Completed,EGFR,1
neoplasm,CETUXIMAB,1,Withdrawn,EGFR,1
neoplasm,CETUXIMAB,2,Unknown status,EGFR,1
neoplasm,ERLOTINIB,1,Recruiting,EGFR,1
neoplasm,CETUXIMAB,4,n/a,EGFR,1
non-small cell lung carcinoma,AFATINIB,4,n/a,EGFR,1
neoplasm,CUDC-101,1,Completed,EGFR,1
non-small cell lung carcinoma,CANERTINIB,1,Completed,EGFR,1
neoplasm,ERLOTINIB,1,"Active, not recruiting",EGFR,1
neoplasm,EPITINIB,1,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,AFATINIB,4,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,AFATINIB,4,Terminated,EGFR,1
neoplasm,VANDETANIB,2,Recruiting,EGFR,1
neoplasm,LAPATINIB,2,Unknown status,EGFR,1
neoplasm,GEFITINIB,3,Completed,EGFR,1
non-small cell lung carcinoma,EGF816,2,Recruiting,EGFR,1
neoplasm,OLMUTINIB,4,n/a,EGFR,1
neuroblastoma,VANDETANIB,1,Terminated,EGFR,1
neoplasm,PANITUMUMAB,4,n/a,EGFR,1
non-small cell lung carcinoma,CETUXIMAB,2,Unknown status,EGFR,1
non-small cell lung carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
non-small cell lung carcinoma,BRIGATINIB,1,Not yet recruiting,EGFR,1
non-small cell lung carcinoma,CUDC-101,1,Completed,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,0,Recruiting,EGFR,1
neoplasm,POZIOTINIB,1,Completed,EGFR,1
neoplasm,NIMOTUZUMAB,1,Completed,EGFR,1
neuroblastoma,LAPATINIB,2,Recruiting,EGFR,1
neoplasm,POZIOTINIB,1,Not yet recruiting,EGFR,1
neuroblastoma,GEFITINIB,2,Completed,EGFR,1
neoplasm,VANDETANIB,4,n/a,EGFR,1
neoplasm,ROCILETINIB,4,n/a,EGFR,1
neoplasm,VANDETANIB,1,Completed,EGFR,1
neoplasm,VANDETANIB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,EGF816,1,"Active, not recruiting",EGFR,1
neoplasm,NIMOTUZUMAB,1,Unknown status,EGFR,1
non-small cell lung carcinoma,CETUXIMAB,2,Recruiting,EGFR,1
neoplasm,GEFITINIB,4,n/a,EGFR,1
non-small cell lung carcinoma,CETUXIMAB,1,Recruiting,EGFR,1
non-small cell lung carcinoma,AFATINIB,2,Not yet recruiting,EGFR,1
neoplasm,IMGATUZUMAB,1,Completed,EGFR,1
neoplasm,LAPATINIB,1,Withdrawn,EGFR,1
neoplasm,LAPATINIB,2,Completed,EGFR,1
non-small cell lung carcinoma,AFATINIB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,2,Suspended,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,2,Not yet recruiting,EGFR,1
neoplasm,LAPATINIB,2,Recruiting,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,2,Enrolling by invitation,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,0,Withdrawn,EGFR,1
neoplasm,LAPATINIB,3,"Active, not recruiting",EGFR,1
neoplasm,LAPATINIB,3,Completed,EGFR,1
neoplasm,LAPATINIB,4,n/a,EGFR,1
non-small cell lung carcinoma,AFATINIB,1,Recruiting,EGFR,1
non-small cell lung carcinoma,AFATINIB,1,Not yet recruiting,EGFR,1
neoplasm,MP-412,1,Terminated,EGFR,1
non-melanoma skin carcinoma,GEFITINIB,1,Unknown status,EGFR,1
neoplasm,NECITUMUMAB,4,n/a,EGFR,1
neoplasm,PELITINIB,1,Completed,EGFR,1
non-small cell lung carcinoma,VANDETANIB,3,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,ERLOTINIB,4,Recruiting,EGFR,1
soft tissue sarcoma,LAPATINIB,3,Not yet recruiting,EGFR,1
salivary gland squamous cell carcinoma,LAPATINIB,2,Completed,EGFR,1
sarcoma,CETUXIMAB,2,Completed,EGFR,1
sarcoma,ERLOTINIB,2,Completed,EGFR,1
sarcoma,GEFITINIB,2,Completed,EGFR,1
skin carcinoma,ERLOTINIB,2,Terminated,EGFR,1
skin carcinoma,GEFITINIB,2,Completed,EGFR,1
skin neoplasm,CETUXIMAB,2,Not yet recruiting,EGFR,1
small cell lung carcinoma,AFATINIB,2,Recruiting,EGFR,1
small cell lung carcinoma,AFATINIB,2,Withdrawn,EGFR,1
small cell lung carcinoma,GEFITINIB,2,Completed,EGFR,1
small cell lung carcinoma,VANDETANIB,2,Completed,EGFR,1
squamous cell carcinoma,AFATINIB,1,Recruiting,EGFR,1
salivary gland squamous cell carcinoma,CETUXIMAB,1,Completed,EGFR,1
squamous cell carcinoma,AFATINIB,2,Not yet recruiting,EGFR,1
squamous cell carcinoma,AFATINIB,2,Recruiting,EGFR,1
squamous cell carcinoma,CETUXIMAB,1,Withdrawn,EGFR,1
squamous cell carcinoma,CETUXIMAB,2,Recruiting,EGFR,1
squamous cell carcinoma,CETUXIMAB,2,Terminated,EGFR,1
squamous cell carcinoma,CETUXIMAB,2,Unknown status,EGFR,1
squamous cell carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
squamous cell carcinoma,ERLOTINIB,2,Completed,EGFR,1
squamous cell carcinoma,ERLOTINIB,2,Terminated,EGFR,1
squamous cell carcinoma,ERLOTINIB,3,Terminated,EGFR,1
squamous cell carcinoma,ERLOTINIB,3,Unknown status,EGFR,1
salivary gland squamous cell carcinoma,CETUXIMAB,2,Completed,EGFR,1
salivary gland neoplasm,GEFITINIB,2,Completed,EGFR,1
polycythemia vera,ERLOTINIB,2,Terminated,EGFR,1
rectum cancer,NIMOTUZUMAB,2,Unknown status,EGFR,1
prostate carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,1
prostate carcinoma,CETUXIMAB,2,Completed,EGFR,1
prostate carcinoma,ERLOTINIB,1,Terminated,EGFR,1
prostate carcinoma,GEFITINIB,2,Terminated,EGFR,1
prostate carcinoma,LAPATINIB,1,Terminated,EGFR,1
prostate carcinoma,PANITUMUMAB,1,Completed,EGFR,1
prostate carcinoma,VANDETANIB,2,Terminated,EGFR,1
psoriasis,ERLOTINIB,2,Withdrawn,EGFR,1
rectum cancer,CETUXIMAB,1,Terminated,EGFR,1
rectum cancer,CETUXIMAB,2,"Active, not recruiting",EGFR,1
rectum cancer,ERLOTINIB,2,Recruiting,EGFR,1
rectum cancer,PANITUMUMAB,1,Completed,EGFR,1
response to drug,POZIOTINIB,2,Completed,EGFR,1
rectum cancer,PANITUMUMAB,2,Completed,EGFR,1
rectum cancer,PANITUMUMAB,2,Recruiting,EGFR,1
rectum cancer,PANITUMUMAB,2,Terminated,EGFR,1
rectum cancer,PANITUMUMAB,2,Unknown status,EGFR,1
rectum cancer,PELITINIB,2,Completed,EGFR,1
renal carcinoma,ERLOTINIB,1,"Active, not recruiting",EGFR,1
renal carcinoma,GEFITINIB,2,Terminated,EGFR,1
renal carcinoma,PANITUMUMAB,1,Completed,EGFR,1
renal carcinoma,VANDETANIB,2,Completed,EGFR,1
renal cell carcinoma,GEFITINIB,1,Completed,EGFR,1
renal cell carcinoma,PANITUMUMAB,2,Completed,EGFR,1
squamous cell carcinoma,FUTUXIMAB,2,Completed,EGFR,1
squamous cell carcinoma,GEFITINIB,2,Completed,EGFR,1
squamous cell carcinoma,GEFITINIB,2,Unknown status,EGFR,1
upper aerodigestive tract neoplasm,GEFITINIB,2,Completed,EGFR,1
transitional cell carcinoma of kidney,VANDETANIB,2,Unknown status,EGFR,1
triple-negative breast cancer,ERLOTINIB,2,Completed,EGFR,1
triple-negative breast cancer,PYROTINIB,1,Recruiting,EGFR,1
upper aerodigestive tract neoplasm,AFATINIB,3,"Active, not recruiting",EGFR,1
upper aerodigestive tract neoplasm,CETUXIMAB,1,Not yet recruiting,EGFR,1
upper aerodigestive tract neoplasm,CETUXIMAB,1,Recruiting,EGFR,1
upper aerodigestive tract neoplasm,CETUXIMAB,1,Unknown status,EGFR,1
upper aerodigestive tract neoplasm,CETUXIMAB,2,"Active, not recruiting",EGFR,1
upper aerodigestive tract neoplasm,CETUXIMAB,2,Terminated,EGFR,1
upper aerodigestive tract neoplasm,CETUXIMAB,4,Unknown status,EGFR,1
upper aerodigestive tract neoplasm,GEFITINIB,1,Completed,EGFR,1
upper aerodigestive tract neoplasm,POZIOTINIB,2,Recruiting,EGFR,1
squamous cell carcinoma,LAPATINIB,2,Terminated,EGFR,1
upper aerodigestive tract neoplasm,ZALUTUMUMAB,1,Completed,EGFR,1
ureteral neoplasm,VANDETANIB,2,Unknown status,EGFR,1
urethral neoplasm,GEFITINIB,2,Completed,EGFR,1
urethral neoplasm,VANDETANIB,2,Unknown status,EGFR,1
urogenital neoplasm,AFATINIB,2,Recruiting,EGFR,1
urothelial carcinoma,PANITUMUMAB,3,Unknown status,EGFR,1
uterine neoplasm,AFATINIB,2,Recruiting,EGFR,1
uterine neoplasm,GEFITINIB,2,Completed,EGFR,1
uterine neoplasm,LAPATINIB,2,Completed,EGFR,1
verrucous carcinoma,CETUXIMAB,1,Completed,EGFR,1
verrucous carcinoma,CETUXIMAB,2,Completed,EGFR,1
transitional cell carcinoma of kidney,LAPATINIB,1,Completed,EGFR,1
transitional cell carcinoma of kidney,GEFITINIB,2,Completed,EGFR,1
tongue neoplasm,CETUXIMAB,2,Completed,EGFR,1
tongue neoplasm,CETUXIMAB,1,Completed,EGFR,1
squamous cell carcinoma,NECITUMUMAB,1,Recruiting,EGFR,1
squamous cell carcinoma,NIMOTUZUMAB,1,Unknown status,EGFR,1
squamous cell carcinoma,NIMOTUZUMAB,2,Terminated,EGFR,1
squamous cell carcinoma,NIMOTUZUMAB,3,Recruiting,EGFR,1
squamous cell carcinoma,PANITUMUMAB,1,"Active, not recruiting",EGFR,1
squamous cell carcinoma,PANITUMUMAB,2,Completed,EGFR,1
squamous cell carcinoma,PANITUMUMAB,2,Unknown status,EGFR,1
squamous cell carcinoma,PANITUMUMAB,3,Terminated,EGFR,1
squamous cell carcinoma,ZALUTUMUMAB,3,Completed,EGFR,1
squamous cell lung carcinoma,ERLOTINIB,1,Terminated,EGFR,1
squamous cell lung carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,1
squamous cell lung carcinoma,ERLOTINIB,2,Recruiting,EGFR,1
squamous cell lung carcinoma,GEFITINIB,3,Completed,EGFR,1
squamous cell lung carcinoma,NECITUMUMAB,2,Recruiting,EGFR,1
stomach neoplasm,CETUXIMAB,2,Unknown status,EGFR,1
stomach neoplasm,GEFITINIB,2,Recruiting,EGFR,1
stomach neoplasm,NIMOTUZUMAB,2,Completed,EGFR,1
stomach neoplasm,NIMOTUZUMAB,2,Recruiting,EGFR,1
thyroid carcinoma,LAPATINIB,1,"Active, not recruiting",EGFR,1
thyroid carcinoma,VANDETANIB,1,Terminated,EGFR,1
thyroid carcinoma,VANDETANIB,4,"Active, not recruiting",EGFR,1
thyroid carcinoma,VANDETANIB,4,n/a,EGFR,1
thyroid neoplasm,VANDETANIB,2,"Active, not recruiting",EGFR,1
prostate adenocarcinoma,CETUXIMAB,2,Terminated,EGFR,1
peritoneal neoplasm,VANDETANIB,2,Completed,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,4,Suspended,EGFR,1
non-small cell lung carcinoma,ROCILETINIB,2,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,PANITUMUMAB,1,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,PANITUMUMAB,1,Completed,EGFR,1
non-small cell lung carcinoma,PANITUMUMAB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,PANITUMUMAB,2,Completed,EGFR,1
non-small cell lung carcinoma,PANITUMUMAB,2,Suspended,EGFR,1
non-small cell lung carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
non-small cell lung carcinoma,PELITINIB,2,Completed,EGFR,1
non-small cell lung carcinoma,PYROTINIB,1,Recruiting,EGFR,1
non-small cell lung carcinoma,ROCILETINIB,1,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,ROCILETINIB,1,Completed,EGFR,1
non-small cell lung carcinoma,ROCILETINIB,1,Terminated,EGFR,1
non-small cell lung carcinoma,ROCILETINIB,2,Terminated,EGFR,1
non-small cell lung carcinoma,OLMUTINIB,1,Completed,EGFR,1
non-small cell lung carcinoma,ROCILETINIB,2,Withdrawn,EGFR,1
non-small cell lung carcinoma,ROCILETINIB,3,Terminated,EGFR,1
non-small cell lung carcinoma,SIMOTINIB,1,Unknown status,EGFR,1
non-small cell lung carcinoma,VANDETANIB,1,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,VANDETANIB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,VANDETANIB,2,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,VANDETANIB,2,Unknown status,EGFR,1
non-small cell lung carcinoma,VANDETANIB,2,Withdrawn,EGFR,1
non-small cell lung carcinoma,ZALUTUMUMAB,2,Terminated,EGFR,1
non-small cell lung carcinoma,ZALUTUMUMAB,2,Withdrawn,EGFR,1
oligoastrocytoma,ERLOTINIB,1,Completed,EGFR,1
non-small cell lung carcinoma,OLMUTINIB,2,Completed,EGFR,1
non-small cell lung carcinoma,NIMOTUZUMAB,2,Recruiting,EGFR,1
peritoneal neoplasm,PANITUMUMAB,2,Terminated,EGFR,1
non-small cell lung carcinoma,LAPATINIB,1,Completed,EGFR,1
non-small cell lung carcinoma,ERLOTINIB,4,Unknown status,EGFR,1
non-small cell lung carcinoma,FUTUXIMAB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,GEFITINIB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,GEFITINIB,2,Suspended,EGFR,1
non-small cell lung carcinoma,GEFITINIB,2,Withdrawn,EGFR,1
non-small cell lung carcinoma,GEFITINIB,4,Not yet recruiting,EGFR,1
non-small cell lung carcinoma,GEFITINIB,4,Recruiting,EGFR,1
non-small cell lung carcinoma,GEFITINIB,4,Unknown status,EGFR,1
non-small cell lung carcinoma,GEFITINIB,4,n/a,EGFR,1
non-small cell lung carcinoma,IMGATUZUMAB,1,Withdrawn,EGFR,1
non-small cell lung carcinoma,IMGATUZUMAB,2,Completed,EGFR,1
non-small cell lung carcinoma,LAPATINIB,2,Terminated,EGFR,1
non-small cell lung carcinoma,NIMOTUZUMAB,2,Completed,EGFR,1
non-small cell lung carcinoma,MATUZUMAB,2,Completed,EGFR,1
non-small cell lung carcinoma,NECITUMUMAB,2,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,NECITUMUMAB,2,Terminated,EGFR,1
non-small cell lung carcinoma,NECITUMUMAB,2,Withdrawn,EGFR,1
non-small cell lung carcinoma,NECITUMUMAB,3,"Active, not recruiting",EGFR,1
non-small cell lung carcinoma,NECITUMUMAB,3,Suspended,EGFR,1
non-small cell lung carcinoma,NECITUMUMAB,4,n/a,EGFR,1
non-small cell lung carcinoma,NIMOTUZUMAB,1,Recruiting,EGFR,1
non-small cell lung carcinoma,NIMOTUZUMAB,1,Terminated,EGFR,1
non-small cell lung carcinoma,NIMOTUZUMAB,1,Unknown status,EGFR,1
non-small cell lung carcinoma,NIMOTUZUMAB,1,Withdrawn,EGFR,1
oligoastrocytoma,ERLOTINIB,1,Terminated,EGFR,1
oligoastrocytoma,VANDETANIB,2,Completed,EGFR,1
oral squamous cell carcinoma,VANDETANIB,2,"Active, not recruiting",EGFR,1
pancreatic carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
pancreatic carcinoma,ERLOTINIB,1,Withdrawn,EGFR,1
pancreatic carcinoma,ERLOTINIB,2,Suspended,EGFR,1
pancreatic carcinoma,ERLOTINIB,2,Unknown status,EGFR,1
pancreatic carcinoma,ERLOTINIB,3,Unknown status,EGFR,1
pancreatic carcinoma,ERLOTINIB,4,Terminated,EGFR,1
pancreatic carcinoma,GEFITINIB,1,Completed,EGFR,1
pancreatic carcinoma,LAPATINIB,2,Completed,EGFR,1
pancreatic carcinoma,NIMOTUZUMAB,2,Completed,EGFR,1
pancreatic carcinoma,NIMOTUZUMAB,3,Unknown status,EGFR,1
pancreatic carcinoma,NIMOTUZUMAB,4,Not yet recruiting,EGFR,1
pancreatic carcinoma,PANITUMUMAB,1,Terminated,EGFR,1
pancreatic carcinoma,PANITUMUMAB,2,Withdrawn,EGFR,1
oropharynx cancer,CETUXIMAB,1,Withdrawn,EGFR,1
pancreatic carcinoma,VANDETANIB,1,Completed,EGFR,1
pancreatic carcinoma,VANDETANIB,2,Unknown status,EGFR,1
pancreatic carcinoma,VARLITINIB,1,Completed,EGFR,1
pancreatic neoplasm,ERLOTINIB,1,Recruiting,EGFR,1
pancreatic neoplasm,ERLOTINIB,2,Completed,EGFR,1
papillary renal cell carcinoma,ERLOTINIB,2,Completed,EGFR,1
papillary thyroid carcinoma,VANDETANIB,2,Recruiting,EGFR,1
peritoneal neoplasm,ERLOTINIB,1,Completed,EGFR,1
peritoneal neoplasm,ERLOTINIB,3,Completed,EGFR,1
peritoneal neoplasm,GEFITINIB,1,"Active, not recruiting",EGFR,1
peritoneal neoplasm,LAPATINIB,2,Completed,EGFR,1
pancreatic carcinoma,ERLOTINIB,1,Unknown status,EGFR,1
pancreatic carcinoma,ERLOTINIB,1,Recruiting,EGFR,1
pancreatic carcinoma,CETUXIMAB,3,Completed,EGFR,1
pancreatic carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
oropharynx cancer,CETUXIMAB,2,Recruiting,EGFR,1
ovarian carcinoma,CETUXIMAB,2,Terminated,EGFR,1
ovarian carcinoma,ERLOTINIB,1,Completed,EGFR,1
ovarian carcinoma,ERLOTINIB,2,Terminated,EGFR,1
ovarian carcinoma,ERLOTINIB,3,Completed,EGFR,1
ovarian carcinoma,GEFITINIB,1,"Active, not recruiting",EGFR,1
ovarian carcinoma,LAPATINIB,1,Terminated,EGFR,1
ovarian carcinoma,LAPATINIB,2,Completed,EGFR,1
ovarian carcinoma,MATUZUMAB,2,Completed,EGFR,1
ovarian carcinoma,PANITUMUMAB,2,Completed,EGFR,1
ovarian carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
ovarian carcinoma,PANITUMUMAB,2,Unknown status,EGFR,1
ovarian carcinoma,VANDETANIB,1,Terminated,EGFR,1
ovarian carcinoma,VANDETANIB,2,Completed,EGFR,1
ovarian neoplasm,ERLOTINIB,2,Completed,EGFR,1
pancreatic adenocarcinoma,CETUXIMAB,2,Completed,EGFR,1
pancreatic adenocarcinoma,ERLOTINIB,1,Completed,EGFR,1
pancreatic adenocarcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,1
pancreatic adenocarcinoma,ERLOTINIB,2,Recruiting,EGFR,1
pancreatic adenocarcinoma,ERLOTINIB,2,Withdrawn,EGFR,1
pancreatic carcinoma,AFATINIB,1,"Active, not recruiting",EGFR,1
pancreatic carcinoma,CETUXIMAB,1,Terminated,EGFR,1
pancreatic carcinoma,CETUXIMAB,1,Unknown status,EGFR,1
neoplasm,CETUXIMAB,1,Not yet recruiting,EGFR,1
Autosomal dominant polycystic kidney disease,TESEVATINIB,1,"Active, not recruiting",EGFR,1
neoplasm,CEP-32496,1,Completed,EGFR,1
central nervous system cancer,GEFITINIB,1,Completed,EGFR,1
carcinoma,ERLOTINIB,2,Unknown status,EGFR,1
carcinoma,ERLOTINIB,3,Completed,EGFR,1
carcinoma,PANITUMUMAB,2,Completed,EGFR,1
carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
central nervous system cancer,AC-480,1,Completed,EGFR,1
central nervous system cancer,AEE-788,1,Completed,EGFR,1
central nervous system cancer,AFATINIB,2,Completed,EGFR,1
central nervous system cancer,CETUXIMAB,2,Completed,EGFR,1
central nervous system cancer,ERLOTINIB,1,Terminated,EGFR,1
central nervous system cancer,ERLOTINIB,1,Unknown status,EGFR,1
central nervous system cancer,ERLOTINIB,2,Unknown status,EGFR,1
central nervous system cancer,FUTUXIMAB,2,Recruiting,EGFR,1
central nervous system cancer,LAPATINIB,1,Completed,EGFR,1
cancer,ERLOTINIB,1,Withdrawn,EGFR,1
central nervous system cancer,LAPATINIB,2,Completed,EGFR,1
central nervous system cancer,MAB-425,2,Completed,EGFR,1
central nervous system cancer,MDX-447,1,Completed,EGFR,1
central nervous system cancer,PANITUMUMAB,2,Terminated,EGFR,1
cervical adenocarcinoma,NIMOTUZUMAB,1,Completed,EGFR,1
cervical carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,1
cervical carcinoma,CETUXIMAB,2,Terminated,EGFR,1
cervical carcinoma,CETUXIMAB,2,Unknown status,EGFR,1
cervical carcinoma,ERLOTINIB,1,Withdrawn,EGFR,1
cervical carcinoma,GEFITINIB,2,Completed,EGFR,1
cervical carcinoma,LAPATINIB,2,Completed,EGFR,1
cervical carcinoma,NIMOTUZUMAB,3,Completed,EGFR,1
carcinoma,ERLOTINIB,2,Completed,EGFR,1
carcinoma,ERLOTINIB,1,Terminated,EGFR,1
carcinoma,CETUXIMAB,2,Unknown status,EGFR,1
carcinoid syndrome,PANITUMUMAB,2,Withdrawn,EGFR,1
cancer,ERLOTINIB,3,Unknown status,EGFR,1
cancer,GEFITINIB,2,Completed,EGFR,1
cancer,GEFITINIB,3,Completed,EGFR,1
cancer,GEFITINIB,3,Enrolling by invitation,EGFR,1
cancer,GEFITINIB,3,Unknown status,EGFR,1
cancer,JNJ-26483327,1,Completed,EGFR,1
cancer,LAPATINIB,0,Terminated,EGFR,1
cancer,LAPATINIB,1,"Active, not recruiting",EGFR,1
cancer,LAPATINIB,2,"Active, not recruiting",EGFR,1
cancer,LAPATINIB,3,Completed,EGFR,1
cancer,LAPATINIB,4,Completed,EGFR,1
cancer,MP-412,1,Completed,EGFR,1
cancer,NIMOTUZUMAB,1,Not yet recruiting,EGFR,1
cancer,PANITUMUMAB,1,Terminated,EGFR,1
cancer,PANITUMUMAB,2,"Active, not recruiting",EGFR,1
cancer,PANITUMUMAB,2,Completed,EGFR,1
cancer,PANITUMUMAB,2,Recruiting,EGFR,1
cancer,PANITUMUMAB,2,Withdrawn,EGFR,1
cancer,PANITUMUMAB,4,Recruiting,EGFR,1
cancer,POZIOTINIB,1,Completed,EGFR,1
cancer,TAK-285,1,Completed,EGFR,1
cancer,THELIATINIB,1,Completed,EGFR,1
cancer,THELIATINIB,1,Terminated,EGFR,1
cancer,VANDETANIB,1,Recruiting,EGFR,1
cancer,VANDETANIB,2,Completed,EGFR,1
cervical carcinoma,NIMOTUZUMAB,3,Recruiting,EGFR,1
cervical carcinoma,PANITUMUMAB,2,Unknown status,EGFR,1
cervical squamous cell carcinoma,CETUXIMAB,2,Completed,EGFR,1
colorectal carcinoma,CETUXIMAB,1,"Active, not recruiting",EGFR,1
colorectal carcinoma,CETUXIMAB,2,Suspended,EGFR,1
colorectal carcinoma,CETUXIMAB,3,"Active, not recruiting",EGFR,1
colorectal carcinoma,CETUXIMAB,3,Withdrawn,EGFR,1
colorectal carcinoma,DULIGOTUZUMAB,2,Completed,EGFR,1
colorectal carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,1
colorectal carcinoma,ERLOTINIB,2,Completed,EGFR,1
colorectal carcinoma,GEFITINIB,1,Terminated,EGFR,1
colorectal carcinoma,IMGATUZUMAB,2,Completed,EGFR,1
colorectal carcinoma,LAPATINIB,1,Recruiting,EGFR,1
colorectal carcinoma,LAPATINIB,2,Completed,EGFR,1
colorectal carcinoma,NIMOTUZUMAB,2,Terminated,EGFR,1
colorectal carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
colorectal carcinoma,PANITUMUMAB,3,Recruiting,EGFR,1
colorectal carcinoma,PANITUMUMAB,3,Unknown status,EGFR,1
colorectal carcinoma,VANDETANIB,2,Completed,EGFR,1
colorectal carcinoma,ZALUTUMUMAB,1,Terminated,EGFR,1
colorectal neoplasm,CETUXIMAB,1,"Active, not recruiting",EGFR,1
colorectal neoplasm,CETUXIMAB,1,Recruiting,EGFR,1
colorectal neoplasm,CETUXIMAB,2,Not yet recruiting,EGFR,1
colorectal neoplasm,CETUXIMAB,2,Recruiting,EGFR,1
colorectal neoplasm,CETUXIMAB,2,Terminated,EGFR,1
colorectal neoplasm,PANITUMUMAB,2,Terminated,EGFR,1
colorectal neoplasm,PANITUMUMAB,3,Recruiting,EGFR,1
colorectal neoplasm,PELITINIB,2,Completed,EGFR,1
cutaneous squamous cell carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,1
colorectal carcinoma,CETUXIMAB,1,Unknown status,EGFR,1
colorectal cancer,PANITUMUMAB,2,Recruiting,EGFR,1
cervical squamous cell carcinoma,ERLOTINIB,2,Completed,EGFR,1
colorectal cancer,NIMOTUZUMAB,2,Unknown status,EGFR,1
cervical squamous cell carcinoma,NIMOTUZUMAB,2,Recruiting,EGFR,1
cholangiocarcinoma,CETUXIMAB,2,Unknown status,EGFR,1
cholangiocarcinoma,VARLITINIB,2,Completed,EGFR,1
chronic kidney disease,LAPATINIB,1,Completed,EGFR,1
clear cell renal carcinoma,ERLOTINIB,1,Completed,EGFR,1
clear cell renal carcinoma,VANDETANIB,2,Terminated,EGFR,1
colon carcinoma,CETUXIMAB,1,Completed,EGFR,1
colon carcinoma,CETUXIMAB,1,Terminated,EGFR,1
colon carcinoma,CETUXIMAB,2,Completed,EGFR,1
colon carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
colon carcinoma,ERLOTINIB,1,"Active, not recruiting",EGFR,1
colon carcinoma,PANITUMUMAB,1,Completed,EGFR,1
colon carcinoma,PANITUMUMAB,2,Completed,EGFR,1
colon carcinoma,PANITUMUMAB,2,Recruiting,EGFR,1
colonic neoplasm,PELITINIB,2,Completed,EGFR,1
colorectal adenocarcinoma,CETUXIMAB,2,Completed,EGFR,1
colorectal adenocarcinoma,CETUXIMAB,2,Unknown status,EGFR,1
colorectal adenocarcinoma,CETUXIMAB,3,Completed,EGFR,1
colorectal adenocarcinoma,CETUXIMAB,4,n/a,EGFR,1
colorectal adenocarcinoma,LAPATINIB,1,Completed,EGFR,1
colorectal adenocarcinoma,PANITUMUMAB,1,Completed,EGFR,1
colorectal adenocarcinoma,PANITUMUMAB,2,Completed,EGFR,1
colorectal adenocarcinoma,PANITUMUMAB,2,Recruiting,EGFR,1
colorectal adenocarcinoma,PANITUMUMAB,4,n/a,EGFR,1
colorectal cancer,CETUXIMAB,1,Not yet recruiting,EGFR,1
cancer,ERLOTINIB,2,Withdrawn,EGFR,1
cancer,ERLOTINIB,1,Recruiting,EGFR,1
diffuse intrinsic pontine glioma,ERLOTINIB,2,Completed,EGFR,1
biliary tract neoplasm,VARLITINIB,1,Recruiting,EGFR,1
anal neoplasm,CETUXIMAB,2,"Active, not recruiting",EGFR,1
anal neoplasm,CETUXIMAB,2,Completed,EGFR,1
anal neoplasm,CETUXIMAB,2,Unknown status,EGFR,1
anaplastic astrocytoma,CETUXIMAB,1,Completed,EGFR,1
anaplastic astrocytoma,ERLOTINIB,1,Terminated,EGFR,1
anaplastic astrocytoma,VANDETANIB,2,Completed,EGFR,1
anaplastic large cell lymphoma,BRIGATINIB,2,Recruiting,EGFR,1
anaplastic oligodendroglioma,ERLOTINIB,1,Terminated,EGFR,1
anaplastic oligodendroglioma,VANDETANIB,2,Completed,EGFR,1
biliary tract neoplasm,CETUXIMAB,2,Completed,EGFR,1
biliary tract neoplasm,ERLOTINIB,2,Not yet recruiting,EGFR,1
biliary tract neoplasm,VARLITINIB,1,Completed,EGFR,1
biliary tract neoplasm,VARLITINIB,2,Withdrawn,EGFR,1
cancer,CUDC-101,1,Terminated,EGFR,1
bladder carcinoma,CETUXIMAB,2,Completed,EGFR,1
bladder carcinoma,ERLOTINIB,2,Terminated,EGFR,1
bladder carcinoma,GEFITINIB,2,Terminated,EGFR,1
bladder carcinoma,GEFITINIB,3,Terminated,EGFR,1
bladder carcinoma,LAPATINIB,0,Terminated,EGFR,1
bladder carcinoma,LAPATINIB,1,Completed,EGFR,1
bladder carcinoma,LAPATINIB,2,Terminated,EGFR,1
bladder carcinoma,LAPATINIB,2,Unknown status,EGFR,1
bladder carcinoma,VANDETANIB,2,Unknown status,EGFR,1
bladder transitional cell carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,1
bladder transitional cell carcinoma,VANDETANIB,2,Completed,EGFR,1
brain disease,LAPATINIB,3,Completed,EGFR,1
anal neoplasm,CETUXIMAB,1,"Active, not recruiting",EGFR,1
adenosquamous lung carcinoma,ERLOTINIB,2,Completed,EGFR,1
adenoid cystic carcinoma,CETUXIMAB,1,Unknown status,EGFR,1
adenocarcinoma,NIMOTUZUMAB,2,Withdrawn,EGFR,1
Brain Stem Glioma,ERLOTINIB,1,Completed,EGFR,1
Chordoma,AFATINIB,2,Recruiting,EGFR,1
Chordoma,CETUXIMAB,1,Not yet recruiting,EGFR,1
Chronic Hepatitis C infection,ERLOTINIB,1,Unknown status,EGFR,1
Digestive System Carcinoma,CETUXIMAB,1,Completed,EGFR,1
Digestive System Carcinoma,PANITUMUMAB,2,Completed,EGFR,1
Ebola hemorrhagic fever,ERLOTINIB,1,Unknown status,EGFR,1
Fallopian Tube Carcinoma,CETUXIMAB,2,Completed,EGFR,1
Fallopian Tube Carcinoma,ERLOTINIB,1,Completed,EGFR,1
Fallopian Tube Carcinoma,ERLOTINIB,3,Completed,EGFR,1
Fallopian Tube Carcinoma,GEFITINIB,1,"Active, not recruiting",EGFR,1
Fallopian Tube Carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
Fallopian Tube Carcinoma,VANDETANIB,2,Completed,EGFR,1
Familial adenomatous polyposis,ERLOTINIB,2,Completed,EGFR,1
Familial adenomatous polyposis,ERLOTINIB,2,Recruiting,EGFR,1
Gastrointestinal stromal tumor,VANDETANIB,2,"Active, not recruiting",EGFR,1
Meningioma,ERLOTINIB,1,Completed,EGFR,1
Penile Carcinoma,AFATINIB,2,Recruiting,EGFR,1
Pituitary Gland Adenoma,LAPATINIB,2,Completed,EGFR,1
Poorly Differentiated Thyroid Gland Carcinoma,VANDETANIB,2,Recruiting,EGFR,1
Thymoma,ERLOTINIB,2,Completed,EGFR,1
acute myeloid leukemia,ERLOTINIB,2,Recruiting,EGFR,1
acute myeloid leukemia,GEFITINIB,2,Completed,EGFR,1
acute myeloid leukemia,VANDETANIB,2,Recruiting,EGFR,1
adenocarcinoma,LAPATINIB,2,Completed,EGFR,1
brain neoplasm,AFATINIB,1,Recruiting,EGFR,1
brain neoplasm,CETUXIMAB,2,"Active, not recruiting",EGFR,1
brain neoplasm,ERLOTINIB,2,Terminated,EGFR,1
breast carcinoma,PYROTINIB,2,Not yet recruiting,EGFR,1
breast carcinoma,PYROTINIB,3,"Active, not recruiting",EGFR,1
breast carcinoma,PYROTINIB,3,Not yet recruiting,EGFR,1
breast carcinoma,TESEVATINIB,1,Terminated,EGFR,1
breast carcinoma,VANDETANIB,1,Completed,EGFR,1
breast carcinoma,VANDETANIB,2,Completed,EGFR,1
breast carcinoma,VANDETANIB,2,Recruiting,EGFR,1
breast ductal adenocarcinoma,LAPATINIB,2,Unknown status,EGFR,1
breast neoplasm,AFATINIB,1,Completed,EGFR,1
breast neoplasm,AFATINIB,3,Completed,EGFR,1
breast neoplasm,CANERTINIB,2,Completed,EGFR,1
breast neoplasm,CETUXIMAB,1,Unknown status,EGFR,1
breast neoplasm,CETUXIMAB,2,Completed,EGFR,1
breast neoplasm,ERLOTINIB,1,"Active, not recruiting",EGFR,1
breast neoplasm,GEFITINIB,2,Completed,EGFR,1
breast neoplasm,LAPATINIB,1,Terminated,EGFR,1
breast neoplasm,LAPATINIB,4,"Active, not recruiting",EGFR,1
breast neoplasm,PANITUMUMAB,2,Recruiting,EGFR,1
breast neoplasm,VANDETANIB,2,Completed,EGFR,1
bronchial neoplasm,EGF816,1,Recruiting,EGFR,1
bronchoalveolar adenocarcinoma,ERLOTINIB,2,Unknown status,EGFR,1
cancer,AEE-788,1,Completed,EGFR,1
cancer,CETUXIMAB,1,Terminated,EGFR,1
cancer,CETUXIMAB,1,Withdrawn,EGFR,1
cancer,CETUXIMAB,2,Recruiting,EGFR,1
cancer,CETUXIMAB,3,"Active, not recruiting",EGFR,1
breast carcinoma,PYROTINIB,2,Recruiting,EGFR,1
breast carcinoma,PYROTINIB,1,"Active, not recruiting",EGFR,1
brain stem neoplasm,NIMOTUZUMAB,2,Recruiting,EGFR,1
breast carcinoma,POZIOTINIB,2,Unknown status,EGFR,1
breast carcinoma,AFATINIB,2,Completed,EGFR,1
breast carcinoma,AFATINIB,2,Unknown status,EGFR,1
breast carcinoma,BMS-690514,2,Completed,EGFR,1
breast carcinoma,CETUXIMAB,1,Unknown status,EGFR,1
breast carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,1
breast carcinoma,CUDC-101,1,Completed,EGFR,1
breast carcinoma,ERLOTINIB,1,"Active, not recruiting",EGFR,1
breast carcinoma,ERLOTINIB,2,Unknown status,EGFR,1
breast carcinoma,ERLOTINIB,2,Withdrawn,EGFR,1
breast carcinoma,GEFITINIB,1,Completed,EGFR,1
breast carcinoma,GEFITINIB,2,Unknown status,EGFR,1
breast carcinoma,GEFITINIB,2,Withdrawn,EGFR,1
breast carcinoma,GEFITINIB,3,Completed,EGFR,1
breast carcinoma,LAPATINIB,0,"Active, not recruiting",EGFR,1
breast carcinoma,LAPATINIB,1,Recruiting,EGFR,1
breast carcinoma,LAPATINIB,1,Suspended,EGFR,1
breast carcinoma,LAPATINIB,4,n/a,EGFR,1
breast carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,1
breast carcinoma,PANITUMUMAB,2,"Active, not recruiting",EGFR,1
breast carcinoma,PANITUMUMAB,2,Completed,EGFR,1
breast carcinoma,PANITUMUMAB,2,Recruiting,EGFR,1
breast carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
breast carcinoma,POZIOTINIB,1,"Active, not recruiting",EGFR,1
breast carcinoma,POZIOTINIB,2,"Active, not recruiting",EGFR,1
breast carcinoma,POZIOTINIB,2,Recruiting,EGFR,1
diffuse gastric adenocarcinoma,LAPATINIB,2,Completed,EGFR,1
diffuse intrinsic pontine glioma,ERLOTINIB,2,Recruiting,EGFR,1
neoplasm,BRIGATINIB,4,n/a,EGFR,1
lung carcinoma,CETUXIMAB,1,Terminated,EGFR,1
lung adenocarcinoma,ERLOTINIB,1,Recruiting,EGFR,1
lung adenocarcinoma,ERLOTINIB,1,Terminated,EGFR,1
lung adenocarcinoma,ERLOTINIB,4,Unknown status,EGFR,1
lung adenocarcinoma,GEFITINIB,3,Completed,EGFR,1
lung adenocarcinoma,POZIOTINIB,2,Completed,EGFR,1
lung adenocarcinoma,POZIOTINIB,2,Terminated,EGFR,1
lung carcinoma,AFATINIB,2,Completed,EGFR,1
lung carcinoma,AFATINIB,2,Recruiting,EGFR,1
lung carcinoma,AFATINIB,2,Terminated,EGFR,1
lung carcinoma,AFATINIB,2,Withdrawn,EGFR,1
lung carcinoma,CANERTINIB,2,Completed,EGFR,1
lung carcinoma,CETUXIMAB,1,Completed,EGFR,1
lung carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,1
head and neck squamous cell carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
lung carcinoma,CETUXIMAB,2,Terminated,EGFR,1
lung carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
lung carcinoma,CETUXIMAB,3,"Active, not recruiting",EGFR,1
Autosomal dominant polycystic kidney disease,TESEVATINIB,2,Terminated,EGFR,1
lung carcinoma,EGF816,2,Recruiting,EGFR,1
lung carcinoma,ERLOTINIB,2,Not yet recruiting,EGFR,1
lung carcinoma,ERLOTINIB,2,Withdrawn,EGFR,1
lung carcinoma,GEFITINIB,1,Unknown status,EGFR,1
lung carcinoma,GEFITINIB,1,Withdrawn,EGFR,1
lung carcinoma,GEFITINIB,2,Terminated,EGFR,1
lung carcinoma,GEFITINIB,3,Recruiting,EGFR,1
lung carcinoma,GEFITINIB,3,Terminated,EGFR,1
lung adenocarcinoma,CETUXIMAB,1,Completed,EGFR,1
liver disease,AFATINIB,1,Completed,EGFR,1
leukemia,ERLOTINIB,2,Completed,EGFR,1
laryngeal squamous cell carcinoma,LAPATINIB,2,Completed,EGFR,1
head and neck squamous cell carcinoma,ERLOTINIB,2,Terminated,EGFR,1
head and neck squamous cell carcinoma,ERLOTINIB,3,Completed,EGFR,1
head and neck squamous cell carcinoma,GEFITINIB,3,Completed,EGFR,1
head and neck squamous cell carcinoma,LAPATINIB,2,Completed,EGFR,1
head and neck squamous cell carcinoma,NIMOTUZUMAB,2,Completed,EGFR,1
head and neck squamous cell carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,1
head and neck squamous cell carcinoma,PANITUMUMAB,1,Completed,EGFR,1
head and neck squamous cell carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
head and neck squamous cell carcinoma,VANDETANIB,2,Completed,EGFR,1
hepatocellular carcinoma,CETUXIMAB,1,Completed,EGFR,1
hepatocellular carcinoma,CETUXIMAB,1,Recruiting,EGFR,1
hepatocellular carcinoma,CUDC-101,1,Completed,EGFR,1
hepatocellular carcinoma,ERLOTINIB,1,Completed,EGFR,1
hepatocellular carcinoma,ERLOTINIB,1,Withdrawn,EGFR,1
hepatocellular carcinoma,ERLOTINIB,2,"Active, not recruiting",EGFR,1
hepatocellular carcinoma,ERLOTINIB,3,Completed,EGFR,1
hepatocellular carcinoma,GEFITINIB,2,Completed,EGFR,1
hepatocellular carcinoma,GEFITINIB,2,Unknown status,EGFR,1
hepatocellular carcinoma,VANDETANIB,2,Completed,EGFR,1
hypopharyngeal carcinoma,CETUXIMAB,1,Completed,EGFR,1
hypopharyngeal carcinoma,LAPATINIB,2,Completed,EGFR,1
large cell lung carcinoma,ERLOTINIB,2,Completed,EGFR,1
large cell lung carcinoma,ERLOTINIB,3,Terminated,EGFR,1
laryngeal squamous cell carcinoma,CETUXIMAB,1,Completed,EGFR,1
laryngeal squamous cell carcinoma,CETUXIMAB,2,Completed,EGFR,1
lung carcinoma,NIMOTUZUMAB,2,Recruiting,EGFR,1
lung carcinoma,PANITUMUMAB,1,Completed,EGFR,1
lung carcinoma,PANITUMUMAB,1,Terminated,EGFR,1
metastatic colorectal cancer,NECITUMUMAB,2,Completed,EGFR,1
metastatic colorectal cancer,PANITUMUMAB,2,"Active, not recruiting",EGFR,1
metastatic colorectal cancer,PANITUMUMAB,2,Terminated,EGFR,1
metastatic neoplasm,AFATINIB,1,Terminated,EGFR,1
metastatic prostate cancer,GEFITINIB,1,Completed,EGFR,1
mouth neoplasm,CETUXIMAB,2,Completed,EGFR,1
mouth neoplasm,ERLOTINIB,3,Completed,EGFR,1
multiple myeloma,CETUXIMAB,2,Completed,EGFR,1
multiple myeloma,CETUXIMAB,2,Terminated,EGFR,1
multiple myeloma,VANDETANIB,2,Completed,EGFR,1
myelodysplastic syndrome,ERLOTINIB,1,Completed,EGFR,1
myelodysplastic syndrome,ERLOTINIB,2,Completed,EGFR,1
myelodysplastic syndrome,ERLOTINIB,2,Withdrawn,EGFR,1
nasopharyngeal neoplasm,CETUXIMAB,1,Completed,EGFR,1
nasopharyngeal neoplasm,CETUXIMAB,2,Terminated,EGFR,1
nasopharyngeal neoplasm,CETUXIMAB,2,Unknown status,EGFR,1
nasopharyngeal neoplasm,CETUXIMAB,3,Recruiting,EGFR,1
nasopharyngeal neoplasm,ERLOTINIB,2,Completed,EGFR,1
nasopharyngeal neoplasm,GEFITINIB,1,Completed,EGFR,1
nasopharyngeal neoplasm,NIMOTUZUMAB,2,Completed,EGFR,1
nasopharyngeal neoplasm,NIMOTUZUMAB,4,Unknown status,EGFR,1
neoplasm,AC-480,1,Completed,EGFR,1
neoplasm,AC-480,1,Withdrawn,EGFR,1
neoplasm,AFATINIB,2,Completed,EGFR,1
neoplasm,AFATINIB,2,Terminated,EGFR,1
neoplasm,AFATINIB,4,n/a,EGFR,1
metastatic colorectal cancer,PANITUMUMAB,1,"Active, not recruiting",EGFR,1
metastatic colorectal cancer,LAPATINIB,2,Completed,EGFR,1
lung carcinoma,PANITUMUMAB,2,"Active, not recruiting",EGFR,1
metastatic colorectal cancer,LAPATINIB,2,"Active, not recruiting",EGFR,1
lymphoma,LAPATINIB,1,Completed,EGFR,1
male breast carcinoma,GEFITINIB,2,Completed,EGFR,1
male breast carcinoma,LAPATINIB,1,"Active, not recruiting",EGFR,1
male breast carcinoma,LAPATINIB,1,Completed,EGFR,1
male breast carcinoma,LAPATINIB,2,Terminated,EGFR,1
male breast carcinoma,LAPATINIB,3,"Active, not recruiting",EGFR,1
malignant peritoneal mesothelioma,ERLOTINIB,2,Completed,EGFR,1
melanoma,ERLOTINIB,1,"Active, not recruiting",EGFR,1
melanoma,ERLOTINIB,2,Completed,EGFR,1
melanoma,LAPATINIB,2,Terminated,EGFR,1
mesothelioma,VANDETANIB,2,Terminated,EGFR,1
metastasis,CETUXIMAB,1,"Active, not recruiting",EGFR,1
metastasis,NECITUMUMAB,1,"Active, not recruiting",EGFR,1
metastatic colorectal cancer,AFATINIB,2,Completed,EGFR,1
metastatic colorectal cancer,CETUXIMAB,2,Withdrawn,EGFR,1
metastatic colorectal cancer,CETUXIMAB,3,"Active, not recruiting",EGFR,1
metastatic colorectal cancer,CETUXIMAB,4,Unknown status,EGFR,1
metastatic colorectal cancer,ERLOTINIB,2,"Active, not recruiting",EGFR,1
metastatic colorectal cancer,ERLOTINIB,2,Unknown status,EGFR,1
metastatic colorectal cancer,ERLOTINIB,3,Completed,EGFR,1
metastatic colorectal cancer,FUTUXIMAB,1,Completed,EGFR,1
metastatic colorectal cancer,FUTUXIMAB,1,Terminated,EGFR,1
metastatic colorectal cancer,FUTUXIMAB,2,Completed,EGFR,1
metastatic colorectal cancer,FUTUXIMAB,2,Withdrawn,EGFR,1
metastatic colorectal cancer,GEFITINIB,2,Withdrawn,EGFR,1
head and neck squamous cell carcinoma,ERLOTINIB,1,Withdrawn,EGFR,1
head and neck squamous cell carcinoma,CETUXIMAB,2,Unknown status,EGFR,1
diffuse intrinsic pontine glioma,NIMOTUZUMAB,2,Recruiting,EGFR,1
gastric carcinoma,LAPATINIB,2,Terminated,EGFR,1
esophageal squamous cell carcinoma,NIMOTUZUMAB,2,Withdrawn,EGFR,1
esophageal squamous cell carcinoma,NIMOTUZUMAB,3,Recruiting,EGFR,1
esophageal squamous cell carcinoma,PANITUMUMAB,2,Terminated,EGFR,1
esophageal squamous cell carcinoma,POZIOTINIB,2,Not yet recruiting,EGFR,1
follicular thyroid carcinoma,VANDETANIB,2,Recruiting,EGFR,1
gastric adenocarcinoma,LAPATINIB,2,Completed,EGFR,1
gastric adenocarcinoma,PANITUMUMAB,2,Terminated,EGFR,1
gastric carcinoma,CETUXIMAB,1,Completed,EGFR,1
gastric carcinoma,CETUXIMAB,1,Terminated,EGFR,1
gastric carcinoma,CETUXIMAB,3,Completed,EGFR,1
gastric carcinoma,CUDC-101,1,Completed,EGFR,1
gastric carcinoma,GEFITINIB,1,Terminated,EGFR,1
gastric carcinoma,LAPATINIB,2,Unknown status,EGFR,1
head and neck squamous cell carcinoma,CETUXIMAB,2,Terminated,EGFR,1
gastric carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,1
gastric carcinoma,POZIOTINIB,1,Completed,EGFR,1
gastric carcinoma,PYROTINIB,1,Recruiting,EGFR,1
gastric carcinoma,PYROTINIB,1,Unknown status,EGFR,1
gastric carcinoma,VANDETANIB,2,Terminated,EGFR,1
gastric carcinoma,VARLITINIB,2,"Active, not recruiting",EGFR,1
gastric intestinal type adenocarcinoma,LAPATINIB,2,Completed,EGFR,1
germ cell tumor,ERLOTINIB,2,Terminated,EGFR,1
germ cell tumor,GEFITINIB,2,Terminated,EGFR,1
glioblastoma multiforme,AEE-788,1,Completed,EGFR,1
glioblastoma multiforme,AFATINIB,1,Completed,EGFR,1
glioblastoma multiforme,CETUXIMAB,1,Completed,EGFR,1
esophageal squamous cell carcinoma,NIMOTUZUMAB,2,Unknown status,EGFR,1
esophageal squamous cell carcinoma,NIMOTUZUMAB,2,Suspended,EGFR,1
esophageal squamous cell carcinoma,NIMOTUZUMAB,2,Not yet recruiting,EGFR,1
esophageal squamous cell carcinoma,LAPATINIB,2,Terminated,EGFR,1
diffuse intrinsic pontine glioma,VANDETANIB,1,Completed,EGFR,1
endometrial carcinoma,LAPATINIB,2,Completed,EGFR,1
endometrial neoplasm,CETUXIMAB,2,Completed,EGFR,1
endometrial neoplasm,ERLOTINIB,2,Completed,EGFR,1
endometrial neoplasm,LAPATINIB,1,Unknown status,EGFR,1
endometriosis,AFATINIB,1,Not yet recruiting,EGFR,1
esophageal adenocarcinoma,CETUXIMAB,2,Completed,EGFR,1
esophageal adenocarcinoma,PANITUMUMAB,2,Terminated,EGFR,1
esophageal carcinoma,CETUXIMAB,1,Unknown status,EGFR,1
esophageal carcinoma,CETUXIMAB,2,"Active, not recruiting",EGFR,1
esophageal carcinoma,CETUXIMAB,2,Recruiting,EGFR,1
esophageal carcinoma,CETUXIMAB,2,Withdrawn,EGFR,1
esophageal carcinoma,CETUXIMAB,3,"Active, not recruiting",EGFR,1
esophageal carcinoma,ERLOTINIB,1,Unknown status,EGFR,1
esophageal carcinoma,ERLOTINIB,3,Unknown status,EGFR,1
esophageal carcinoma,GEFITINIB,2,Unknown status,EGFR,1
esophageal carcinoma,LAPATINIB,2,Terminated,EGFR,1
esophageal carcinoma,NIMOTUZUMAB,1,Completed,EGFR,1
esophageal carcinoma,NIMOTUZUMAB,2,Recruiting,EGFR,1
esophageal carcinoma,PANITUMUMAB,1,Terminated,EGFR,1
esophageal carcinoma,PANITUMUMAB,2,Completed,EGFR,1
esophageal carcinoma,VANDETANIB,1,Unknown status,EGFR,1
esophageal squamous cell carcinoma,AFATINIB,2,"Active, not recruiting",EGFR,1
esophageal squamous cell carcinoma,CETUXIMAB,2,Completed,EGFR,1
esophageal squamous cell carcinoma,CETUXIMAB,2,Unknown status,EGFR,1
glioblastoma multiforme,CETUXIMAB,1,Recruiting,EGFR,1
glioblastoma multiforme,CETUXIMAB,1,Unknown status,EGFR,1
glioblastoma multiforme,CETUXIMAB,2,Terminated,EGFR,1
head and neck malignant neoplasia,ERLOTINIB,1,Terminated,EGFR,1
head and neck malignant neoplasia,ERLOTINIB,3,Terminated,EGFR,1
head and neck malignant neoplasia,GEFITINIB,1,Terminated,EGFR,1
head and neck malignant neoplasia,GEFITINIB,2,Terminated,EGFR,1
head and neck malignant neoplasia,GEFITINIB,3,Terminated,EGFR,1
head and neck malignant neoplasia,IMGATUZUMAB,1,Completed,EGFR,1
head and neck malignant neoplasia,LAPATINIB,1,Completed,EGFR,1
head and neck malignant neoplasia,NIMOTUZUMAB,2,"Active, not recruiting",EGFR,1
head and neck malignant neoplasia,NIMOTUZUMAB,2,Completed,EGFR,1
head and neck malignant neoplasia,PANITUMUMAB,2,Unknown status,EGFR,1
head and neck malignant neoplasia,PANITUMUMAB,2,Withdrawn,EGFR,1
head and neck malignant neoplasia,PANITUMUMAB,3,Completed,EGFR,1
head and neck malignant neoplasia,PANITUMUMAB,3,Withdrawn,EGFR,1
head and neck malignant neoplasia,VANDETANIB,1,Completed,EGFR,1
head and neck malignant neoplasia,VANDETANIB,2,Terminated,EGFR,1
head and neck malignant neoplasia,ZALUTUMUMAB,1,Completed,EGFR,1
head and neck neoplasia,LAPATINIB,2,Completed,EGFR,1
head and neck neoplasia,LAPATINIB,3,Completed,EGFR,1
head and neck squamous cell carcinoma,AFATINIB,1,"Active, not recruiting",EGFR,1
head and neck squamous cell carcinoma,AFATINIB,1,Terminated,EGFR,1
head and neck squamous cell carcinoma,AFATINIB,2,"Active, not recruiting",EGFR,1
head and neck squamous cell carcinoma,AFATINIB,2,Recruiting,EGFR,1
head and neck squamous cell carcinoma,AFATINIB,3,"Active, not recruiting",EGFR,1
head and neck squamous cell carcinoma,CETUXIMAB,1,Not yet recruiting,EGFR,1
head and neck squamous cell carcinoma,CETUXIMAB,1,Unknown status,EGFR,1
head and neck squamous cell carcinoma,CETUXIMAB,1,Withdrawn,EGFR,1
head and neck malignant neoplasia,ERLOTINIB,2,Terminated,EGFR,1
head and neck malignant neoplasia,ERLOTINIB,1,"Active, not recruiting",EGFR,1
glioblastoma multiforme,DEPATUXIZUMAB MAFODOTIN,1,Completed,EGFR,1
head and neck malignant neoplasia,ERLOTINIB,0,Completed,EGFR,1
glioblastoma multiforme,DEPATUXIZUMAB MAFODOTIN,1,Recruiting,EGFR,1
glioblastoma multiforme,DEPATUXIZUMAB MAFODOTIN,2,Recruiting,EGFR,1
glioblastoma multiforme,DEPATUXIZUMAB MAFODOTIN,3,Recruiting,EGFR,1
glioblastoma multiforme,EPITINIB,1,Recruiting,EGFR,1
glioblastoma multiforme,ERLOTINIB,1,Completed,EGFR,1
glioblastoma multiforme,ERLOTINIB,1,Terminated,EGFR,1
glioblastoma multiforme,ERLOTINIB,2,Completed,EGFR,1
glioblastoma multiforme,GEFITINIB,2,Terminated,EGFR,1
glioblastoma multiforme,LAPATINIB,2,"Active, not recruiting",EGFR,1
glioblastoma multiforme,NIMOTUZUMAB,2,Completed,EGFR,1
glioblastoma multiforme,NIMOTUZUMAB,3,Completed,EGFR,1
glioblastoma multiforme,TESEVATINIB,2,"Active, not recruiting",EGFR,1
glioblastoma multiforme,VANDETANIB,1,Completed,EGFR,1
gliosarcoma,DEPATUXIZUMAB MAFODOTIN,2,Recruiting,EGFR,1
gliosarcoma,ERLOTINIB,1,Terminated,EGFR,1
gliosarcoma,GEFITINIB,1,Completed,EGFR,1
gliosarcoma,GEFITINIB,2,Completed,EGFR,1
gliosarcoma,LAPATINIB,2,Completed,EGFR,1
gliosarcoma,VANDETANIB,2,Completed,EGFR,1
head and neck malignant neoplasia,CETUXIMAB,1,"Active, not recruiting",EGFR,1
head and neck malignant neoplasia,CETUXIMAB,1,Recruiting,EGFR,1
head and neck malignant neoplasia,CETUXIMAB,3,Withdrawn,EGFR,1
head and neck malignant neoplasia,CETUXIMAB,4,Unknown status,EGFR,1
head and neck malignant neoplasia,DULIGOTUZUMAB,1,Completed,EGFR,1
head and neck malignant neoplasia,DULIGOTUZUMAB,2,Completed,EGFR,1
verrucous carcinoma,VANDETANIB,2,"Active, not recruiting",EGFR,1
